Weekly chemotherapy with cisplatin/paclitaxel in the front-line treatment of NSCLC: a phase II study

G. Buccheri, D. Ferrigno, M. C. Giordano (Cuneo, Italy)

Source: Annual Congress 2004 - Thoracic oncology
Session: Thoracic oncology
Session type: Poster Discussion
Number: 4099
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Buccheri, D. Ferrigno, M. C. Giordano (Cuneo, Italy). Weekly chemotherapy with cisplatin/paclitaxel in the front-line treatment of NSCLC: a phase II study. Eur Respir J 2004; 24: Suppl. 48, 4099

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016


A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002

Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 301s
Year: 2004

Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019
Year: 2020



Concurrent chemoradiotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy with vinorelbine for locally advanced inoperable nonsmall-cell lung cancer: A multiinstitutional phase II study
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009

A randomised phase III trial by the European lung cancer working party comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based standard chemotherapy, with the use of taxan as salvage treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 833s
Year: 2006

A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 781s
Year: 2006

Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 12s
Year: 2005

A randomised prospective trial of concurrent chemoradiotherapy (CCRT) with cisplatin and paclitaxel or docetaxel or gemcitabine in stage IIIB nonsmall cell lung cancer
Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer
Year: 2009



A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 186s
Year: 2002

Phase II trial on neoadjuvant chemoradiation with paclitaxel/carboplatin in stage III NSCLC
Source: Annual Congress 2003 - Lung cancer staging and combined modality treatment
Year: 2003


Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial
Source: Eur Respir J 2002; 20: Suppl. 38, 187s
Year: 2002

Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021



Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008

Topotecan in combination with carboplatin and etoposide as first line treatment in SCLC patients: a phase I/II study – final results
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008


Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006

A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005